Medtronic is rapidly boosting its presence in the heart valve market, winning European approval for Engager, a transcatheter aortic valve implantation system to treat patients with aortic stenosis.
Bayer's new drugs are bringing home the bacon. The German drugmaker raised its 2015 forecast for 5 key products to €2.5 billion ($3.3 billion)--and confirmed previous promises that those drugs would surpass €5.5 billion by 2020.
Come July 2, all active pharmaceutical ingredients imported into Europe must be certified that they meet EU regulations by the country of their origin.
As part of an ongoing campaign to streamline the clinical trial process in hopes of spurring its drug R&D industry, U.K. officials are preparing to dismantle patent rules which make it difficult for developers to compare their experimental therapies with currently used standards in clinical studies.
Dublin-based Elan has told investors how it plans to play the first two rounds in a $3.25 billion game set up by the sale of Tysabri. In a statement this morning the biotech company said it will use the first $1 billion in a share buyback aimed at returning some of the money to investors
An increasingly vocal dustup between device companies and European lawmakers will reach a big milestone on Feb. 26, when both sides will meet during a European Parliament committee meeting and begin trying to hash out a way to strengthen medical device regulations.
With the ascent of targeted cancer drugs, a growing number of contract manufacturers are beefing up their cytotoxic manufacturing capabilities to cash in on demand.
Even as stent manufacturers are bumping into each other in Europe vying for business, Boston Scientific ($BSX) is bringing yet another entry into the competition: The Promus Premier.
Swiss coronary stent developer Qvanteq is reeling in more than $4.3 million in series B financing, representing the emergence of yet another stent player in an intensely competitive European market.
European device giant Smith & Nephew posted a 2.3% drop in net profit last quarter, grappling with declining demand for reconstruction tech and plodding through a realignment of its business.